Shilpa Medicare informs about updates

12 Dec 2025 Evaluate

Shilpa Medicare has informed that Shilpa Medicare, headquartered at Raichur, Karnataka, India, has received the Initial Authorization from Europe, recommending the grant of the final Marketing Authorization for Shilpa Medicare’s prescription product, Rotigotine 1, 2, 3, 4, 6, 8 mg/24 h transdermal patch. This application, submitted as a generic application via Decentralized Procedure in Europe and is a generic version of the innovator product Neupro. Shilpa’s product is pharmaceutical and bioequivalent version of the reference product Neupro. Shilpa’s Rotigotine patches are indicated for treatment of Restless Legs Syndrome and Parkinson’s disease. The total addressable European market for Rotigotine is estimated at ~USD 222 million. Shilpa has on boarded a strategic commercialization partner in Europe, with a targeted launch in FY27. 

The above information is a part of company’s filings submitted to BSE.

Shilpa Medicare Share Price

319.70 -4.10 (-1.27%)
16-Dec-2025 11:05 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1788.20
Dr. Reddys Lab 1275.10
Cipla 1503.00
Zydus Lifesciences 920.95
Lupin 2082.55
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×